BOPA and PRUK award their 2016 research grant

BOPA and PRUK are delighted to grant the 2016 BOPA-PRUK Research Award to John Minshull at University College London Hospital.  BOPA and PRUK (Pharmacy Research UK) are working together to help novice researchers in oncology and haematology pharmacy to take their first steps in research.

The project that will be funded is “A qualitative study of the barriers and enablers to administration of supportive therapy closer to home for breast cancer patients”.  The project will be conducted by John Minshull, Joint Formulary Pharmacist at University College London Hospital (UCLH) and Dr Yogini Jani, Medication Safety and Honorary Lecturer at UCLH NHS Foundation Trust and UCL School of Pharmacy.

Helen Flint, immediate past BOPA Chair, said, “BOPA are delighted to be working with PRUK to fund this innovative and clinically relevant project.  In the longer term could save this patient group a significant amount of time travelling to and from the cancer centres and lead to a better quality of experience.  We look forward to continuing the partnership in 2017 to fund further research.”

This project aims to understand the viability of administering the denosumab injections (Xgeva®) closer to the patients’ home via their GP for two specific groups of patients – those whose chemotherapy cycle falls outside the denosumab cycle and those no longer receiving chemotherapy.  These injections are given to patients with or have suffered from solid tumours to prevent skeletal-related metastases.  The project will aim to answer two key questions:

  1. What are the enablers and barriers to GPs in providing denosumab administration for breast cancer patients?
  2. What are the views and opinions of patients about receiving denosumab injections from their GP?

By providing these injections via the patient’s GP rather than a chemotherapy unit (which is where they are administered in the current system) it is hoped to save the NHS money which could be used elsewhere and provide a more convenient place for the patient to receive their injection.

The project will be based in North Central London (Barnet, Camden, Enfield, Haringey and Islington).  GPs working in practices within these areas and patients attending the Macmillan Cancer Centre, University College London Hospital for denosumab injections will be invited to participate in the research.

Dr Jani said, “We are delighted to receive this award.  Many treatments have the potential for delivery through General Practice or other primary care services, with the benefits of improved patient experience and possible savings in the NHS.  By gaining the views of patients receiving denosumab and their GPs, we hope to develop an understanding and evidence base of the drivers and challenges for service redesign.”

The project is due to finish in February 2017 and will make recommendations on the administration of denosumab injections in the final report.

Latest News

By BOPA Committee on 12th July 2024

TRANScribing: Clinical considerations for safe and inclusive prescribing for transgender and non-binary patients

BOPA is delighted to announce the publication of TRANScribing: Clinical considerations for safe and inclusive prescribing for transgender and non-binary patients in collaboration with OUTpatients. It is estimated that one…

Read article
By BOPA Committee on 11th July 2024

Round Table Discussion at #BOPA2024

  As an exciting addition to the 2024 conference, we invite you all to participate in one of our interactive sessions on the Sunday morning. We have a lineup of…

Read article
By BOPA Committee on 10th July 2024

APTUK Position Statement for DHSC PGD Update

The Association of Pharmacy Technicians UK (APTUK), as the professional leadership body for pharmacy technicians, welcome the positive outcome of the DHSC consultation supporting the enabling of registered pharmacy technicians…

Read article
By BOPA Research on 9th July 2024

Last Chance to Submit Your Work to #BOPA2024

Last Chance to Submit: BOPA 2024 Abstract Submission DEADLINE is 14th July 2024. Delegates are invited to present results of their clinical and technical work as a poster with some…

Read article